March 1, 2017 / 11:24 AM / 5 months ago

BRIEF-Alnylam receives European Medicines Agency prime designation for accelerated assessment of givosiran

1 Min Read

March 1 (Reuters) - Alnylam Pharmaceuticals Inc:

* Alnylam receives European Medicines Agency prime designation for accelerated assessment of givosiran, an investigational rnai therapeutic for the treatment of acute hepatic porphyrias

* Says European Medicines Agency (EMA) has granted access to its priority medicines (prime) scheme for givosiran Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below